Stock vs Stock Comparison

Apellis Pharmaceuticals, Inc. vs Eli Lilly and Company

LLY wins the Tale of the Tape 6–2.

APLS
LLY$1064.15

🏆 Tale of the Tape

26
APLSLLY
2.2%Profitability (Net Margin)31.7%
224.4xValuation (P/E)39.2x
7.2%Efficiency (ROIC)30.4%
7/9Health (Piotroski F)7/9
2.4Safety (Altman Z)7.8
28.5%Growth (Rev YoY)44.7%
Risk (Sharpe 1Y)0.61
1.90xBalance Sheet (D/E)3.24x
0.89%FCF Yield0.68%

Green = winner in each category. Higher is better except P/E (lower = cheaper).

Fundamentals

MetricAPLSLLY
Market Cap$5.2B$985.4B
P/E Ratio224.4x39.2x
Forward P/E-131.1x24.8x
P/B13.82x31.65x
Dividend Yield0.63%
Beta0.290.48

Quantitative Metrics

MetricAPLSLLY
DCF Fair Value$9.27$296.11
DCF Upside-68.2%
Piotroski F7/97/9
Altman Z2.397.84
Beneish M-2.45-1.91
FCF Yield0.89%0.68%
Net Debt/EBITDA-1.5x1.1x
ROIC7.2%30.4%
WACC7.7%7.8%
ROIC – WACC-0.5pp22.5pp
Gross Margin89.8%83.0%
Net Margin2.2%31.7%
Rev Growth YoY28.5%44.7%
Sharpe (1Y)0.61
Max Drawdown 3Y
FCF Payout Ratio90%

APLS Price

Loading chart...

LLY Price

Loading chart...

ETF Exposure

APLS found in:

VBK0.13%
VHT0.05%
VONG0.01%

LLY found in:

XLV15.40%
IYH13.72%
VHT12.15%
VIG3.33%
SCHG3.17%
QUAL2.92%
MGK2.82%
IWF2.66%
VONG2.42%
SPYG2.36%
VUG2.31%
IVW2.23%
QUS1.95%
XPH1.90%
ESGV1.48%
DGRW1.46%
IVV1.46%
SCHX1.34%
SPY1.29%
ITOT1.29%
SCHB1.25%
VFQY1.23%
VOO1.20%
SPTM1.20%
VTI1.14%
VONE1.14%
SPLG1.10%
ARKG1.04%
URTH0.99%
ACWI0.87%
VT0.66%
VFMO0.46%
RSP0.20%
ONEO0.02%

More Comparisons

Quant metrics computed from financial statements and 1,200+ trading days. Correlation is Pearson coefficient on daily log returns. Not investment advice.

APLS vs LLY: Head-to-Head Analysis

Apellis Pharmaceuticals, Inc. (APLS) and Eli Lilly and Company (LLY) represent two companies in the Healthcare sector. In our quantitative Tale of the Tape scoring, LLY leads 6–2 across nine fundamental and risk metrics including profitability, valuation, capital efficiency, and financial health.

In terms of capital efficiency, APLS generates a return on invested capital (ROIC) of 7.2% compared to LLY's 30.4%. This suggests LLY is more effective at deploying capital to generate shareholder returns.

APLS appears in 3 ETFs tracked by SecuritiesDB, while LLY appears in 34 ETFs. Investors holding broad-market ETFs may already have indirect exposure to both stocks.

Frequently Asked Questions

Which stock is the better investment, APLS or LLY?

Our quantitative analysis compares APLS and LLY across nine fundamental dimensions. LLY wins the Tale of the Tape 6–2. However, stock selection depends on your individual risk tolerance, time horizon, and portfolio context. These metrics are computed from SEC filings and market data — they are not investment recommendations.

Are APLS and LLY correlated?

Correlation data is not yet available for this pair. Check back after both stocks have sufficient trading history.

How is the Tale of the Tape scored?

The Tale of the Tape compares both stocks across nine categories: profitability (net margin), valuation (P/E), efficiency (ROIC), health (Piotroski F-Score), safety (Altman Z-Score), growth (revenue YoY), risk (Sharpe ratio), leverage (debt-to-equity), and cash generation (FCF yield). The stock that wins more categories takes the overall score. Lower P/E and lower debt-to-equity count as wins.